

# Paradoxical reaction under dupilumab triggered by occasional ketoprofen intake

Filippo Chersi,<sup>1,2\*</sup> Sanja Javor,<sup>1\*</sup> Rosella Gallo,<sup>3</sup> Elia Sala,<sup>1,2</sup> Cesare Massone<sup>4</sup>

<sup>1</sup>Dermatology Unit, Galliera Hospital, Genoa; <sup>2</sup>Dermatology Clinic of Trieste, Maggiore Hospital, University of Trieste; <sup>3</sup>Dermatologic Clinic of Genova, San Martino Hospital, University of Genova; <sup>4</sup>Dermatology Unit & Scientific Directorate, Galliera Hospital, Genoa, Italy

\*These authors share first authorship

## Abstract

Dupilumab, a monoclonal antibody targeting the IL-4/13 signaling pathway, effectively treats moderate-to-severe atopic dermatitis (AD). Common side effects include injection site reactions, conjunctivitis, and respiratory infections. We report the case of a 28-year-old woman with severe AD involving the peri-

ocular and chin regions, genital areas, arms, and legs (Eczema Area and Severity Index [EASI]: 24, itch Visual Analog Scale [VAS]: 8) who showed significant improvement after initiating dupilumab therapy. However, following ketoprofen intake for headache relief, she developed a lupus-like erythematous maculopapular rash on the periocular and malar regions. Immunological tests (antinuclear antibody [ANA] and extractable nuclear antigen [ENA]) and photopatch testing ruled out autoimmune or allergic causes. Dupilumab was stopped, and treatment with oral prednisone and cetirizine led to complete resolution. This case highlights a potential drug interaction between dupilumab and ketoprofen, emphasizing the need for awareness of paradoxical facial erythema reactions in patients undergoing dupilumab therapy.

Correspondence: Filippo Chersi, MD, Dermatology Clinic, Maggiore Hospital, Piazza dell' Ospitale 1, 34129 Trieste, Italy.  
Tel.: +39.0403992056  
E-mail: filippochersi@gmail.com

Key words: dupilumab; atopic dermatitis; paradoxical reaction; ketoprofen.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient gave her written consent to use her personal data for the publication of this case report and any accompanying images.

Availability of data and materials: all data underlying the findings are fully available.

Received: 10 December 2024.

Accepted: 22 February 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Dermatology Reports 2025; 17:10214

doi:10.4081/dr.2025.10214

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Introduction

Dupilumab is a monoclonal antibody that acts on the IL-4/13 signaling pathway, inhibiting downstream activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. It has been proven effective in treating moderate to severe atopic dermatitis (AD), with the most commonly reported side effects being reactions at injection sites, conjunctivitis, nasopharyngitis, and upper respiratory tract infections.<sup>1</sup>

## Case Report

We present the case of a 28-year-old woman with lichenified and fissured AD in the periocular and chin area, genital area, arms, and legs that was highly pruritic and impactful on her quality of life (itch Visual Analog Scale [VAS]: 8; Eczema Area and Severity Index [EASI]: 24) (Figure 1a). She initiated dupilumab therapy with the standard initial dosage of 600 mg, followed by 300 mg every other week. During the first month, after three administrations, a significant improvement was observed, with reduced itching and initial regression of lesions on the face and hands, along with gradual attenuation of genital symptoms (itch VAS: 6; EASI: 6). Subsequently, during a follow-up visit, the patient presented with an erythematous, desquamating maculopapular lupus-like rash in the periocular and malar regions, which developed a few hours after taking ketoprofen for a headache (Figure 1b). Immunological tests (antinuclear antibody [ANA] and extractable nuclear antigen [ENA]) were performed to rule out lupus erythematosus and dermatomyositis, yielding negative results. Additionally, to rule out possible allergic photodermatitis, the



**Figure 1.** a) Atopic dermatitis presenting with eczematous pruritic lesions in the periocular and perioral region; b) erythematous maculopapular rash in the periorbital and malar region; c) complete resolution of the rash a week later after oral steroids and antihistamines

patient underwent a standard patch test series with 40 allergens and a photopatch test. Two identical series were applied to the dorsal skin, and after patch removal at 48 hours, only one of the two was irradiated with a UVA dose of 3 J. Both tests yielded negative results at the 72-hour reading, excluding reactivity to ketoprofen. Dupilumab was temporarily stopped, and the patient was treated with 25 mg of oral prednisone and oral cetirizine for one week, showing complete resolution of the rash (Figure 1c).

## Conclusions

Paradoxical reactions to dupilumab, characterized by localized erythema on the face or neck, have been described in the literature, typically within 6 months of starting dupilumab therapy.<sup>2,3</sup> Given the timing of onset, clinical presentation, and negativity in sensitization to nonsteroidal anti-inflammatory drugs (NSAIDs),

we want to highlight the possibility of drug interaction between dupilumab and ketoprofen that may have triggered the paradoxical reaction in our patient.

## References

1. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. *J Am Acad Dermatol* 2018;78:S28-36.
2. de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. *Br J Dermatol* 2020;183:745-9.
3. Li Y, Liu H, Zhang F. Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis. *Indian J Dermatol* 2023;68:186-91.